ADC Therapeutics SA (ADCT)
| Bid | 1.2 |
| Market Cap | 122.49M |
| Revenue (ttm) | 70.84M |
| Net Income (ttm) | -157.85M |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -0.76 |
| Forward PE | -0.9 |
| Analyst | Buy |
| Ask | 1.28 |
| Volume | 291,140 |
| Avg. Volume (20D) | 397,337 |
| Open | 1.25 |
| Previous Close | 1.23 |
| Day's Range | 1.20 - 1.25 |
| 52-Week Range | 1.05 - 5.17 |
| Beta | 1.56 |
About ADCT
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second...
Analyst Forecast
According to 5 analyst ratings, the average rating for ADCT stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 547.77% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...
